Cytokinetics Inc (Cytokinetics) is a biopharmaceutical company involved in discovering and developing small molecule therapeutics that modulate muscle function for the treatment of diseases and medical conditions. The company operates in the US. The company conducts clinical programs that are focused on muscle contractility. These programs include cardiac muscle contractility program, skeletal muscle contractility program and smooth muscle contractility program. Cytokinetics' cardiac muscle contractility program is focused on the cardiac sarcomere, the basic unit of muscle contraction in the heart. The company's main drug candidate is omecamtiv mecarbil (formerly CK-1827452), a cardiac muscle myosin activator. Omecamtiv mecarbil is under Phase II clinical trial, known as COSMIC-HF (chronic oral study of myosin activation to increase contractility in heart failure). The company's cardiac muscle contractility program includes the discovery and development of small molecule cardiac muscle myosin activators for developing drugs to treat acute and chronic heart failure. Cytokinetics' skeletal muscle contractility program is involved in the activation of skeletal sarcomere, which is the basic unit of skeletal muscle contraction. Under this program, the company's Tirasemtiv (formerly CK-2017357) and CK-2127107 drugs activate the skeletal muscle troponin complex by increasing its sensitivity to calcium, leading to an increase in skeletal muscle contractility. The company's smooth muscle contractility program is focused on the discovery and development of small molecule smooth muscle myosin inhibitors and leverages in muscle function and its application to drug discovery. Under this program, the company conducts preclinical research to develop direct smooth muscle myosin inhibitor compounds for potential use in acute or chronic settings. Cytokinetics’s research and development (R&D) activities primarily concentrate on developing multiple drug candidates and focus on two areas, namely, biology of the cytoskeleton and small molecule modulation of muscle contractility. In FY2016, the company incurred expenses of US$59.8 million on its R&D activities, which accounted for 56.2% of company’s total revenue.
Scope of the Report
-- About the Company - Historical Details, Current Ownership Structure and basic overview of Cytokinetics, Inc. in terms of revenue, net income, and operating income.
-- Financials - Details about Cytokinetics, Inc. listing status, annual financial reports (for the past 5 years), key financial highlights and region wise and category wise breakdown of their net revenue.
-- Products / Services - Listing of the company’s entire portfolio along with description of individual products / services providing a clear picture of their target audience.
-- Company SWOT Analysis - Outlines Cytokinetics, Inc.’s strengths, weaknesses, and opportunities and threats facing the company.
-- Recent Developments - Showcases Cytokinetics, Inc.’s recent developments including mergers, acquisitions, partnerships, collaborations, new product launches, investment and divestment plans.
-- Strategic Evaluation - Provides an overview of Cytokinetics, Inc.’s corporate goals and strategic initiatives and evaluates their outcomes along with outlining any persisting legal issues and outlook of our in-house analyst panel on the particular company.
-- Technology Landscape - Details how the company allocates its IT budget across the core areas of its business, CIO/CTO Profile, Key IT Initiatives and Deals undertaken buy the company at present along with outlook.
Key Questions Answered
-- What domain does Cytokinetics, Inc. operate and what are key points about it?
-- What is the product / service portfolio of Cytokinetics, Inc.?
-- How has Cytokinetics, Inc. performed financially from the 2013?
-- How does Cytokinetics, Inc. rank among its peers in terms of revenue and market share?
-- What are Cytokinetics, Inc. strengths and weaknesses and what opportunities and threats does it face?
-- What are Cytokinetics, Inc.’s main growth strategies and how successful has the company been at implementing them?
-- What is the in-house technical capability of Cytokinetics, Inc.? Where does it procure / outsource it?
Reasons to buy
-- Report delivered in easily accessible PPT format which can be used to gain insights quickly and further prepare presentations of your own
-- Lean pricing structure ultimately giving you vast access to the unlimited knowledge repository of the company profiles at very competitive cost
-- 12 hour delivery time fulfilling your urgent requests as per your requirement
-- On-demand customization options that can completely cater to your needs by focusing the report onto given specifics
1. About the Company
1.1 History and Basic Facts
1.2 Ownership Structure and Key Executives
1.3 Head Office
1.4 Other Locations & Subsidiaries
1.5 List of Competitors
1.6 Employee Count & Distribution
2.1 Company Type (Listed / Unlisted)
2.2 Annual Statements
2.3 Key Financial Highlights
2.4 Region-wise Breakdown
3. Product / Services
4. SWOT Analysis
4.1 SWOT Overview
5. Recent Developments
5.1 Mergers & Acquisitions
5.2 Partnerships, Collaborations & Joint Ventures
5.3 New Product Launches
5.4 Business Expansion / Divestment
6. Strategic Evaluation
6.1 Corporate Strategy
6.2 Legal Issues
6.3 Analyst Outlook
7. Technology Landscape
-- 7.1.1 Industry Snapshot
-- 7.1.2 IT Spend
-- 7.1.3 Key Information Technology Trends
-- 7.2.1 IT Overview
-- 7.2.2 Key IT Technologies
-- 7.2.3 Recent IT Initiatives
-- 7.2.4 IT Outsourcing Engagements
-- 7.2.5 Key IT Management
-- 7.2.6 CIO/CTO Profile
-- About Us
-- Contact Us
Fig.1: Company Snapshot
Fig.2: Locations Listing on Map
Table.1: Ownership Structure
Table.2: List of Competitors
Table.3: Annual Statements
Table.4: Key Financial Highlights
Table.5: Region-wise Breakdown
Table.6: Product/Services Overview
Table.7: Mergers & Acquisitions
Table.8: Partnerships, Collaborations & Joint Ventures
Table.9: New Product Launches
Table.10: Business Expansion / Divestment
Table 11: IT Budgets
Table 12: Key IT Management (CIO / CTO)
Table 13: IT Deals undertaken in the past years